Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP Richard S. Geary sold 5,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $65.06, for a total transaction of $325,300.00. Following the transaction, the senior vice president now directly owns 26,583 shares in the company, valued at $1,729,489.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ IONS traded up $0.82 during trading on Wednesday, reaching $65.00. 872,008 shares of the stock were exchanged, compared to its average volume of 1,130,595. The business’s 50-day moving average price is $58.23 and its 200 day moving average price is $63.02. Ionis Pharmaceuticals Inc has a twelve month low of $48.27 and a twelve month high of $86.58. The company has a quick ratio of 10.31, a current ratio of 10.39 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $9.00 billion, a price-to-earnings ratio of 21.96, a price-to-earnings-growth ratio of 2.30 and a beta of 1.91.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.49. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The business had revenue of $168.00 million for the quarter, compared to analysts’ expectations of $152.47 million. During the same period in the previous year, the company posted ($0.03) earnings per share. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. As a group, sell-side analysts expect that Ionis Pharmaceuticals Inc will post 1.99 earnings per share for the current fiscal year.
A number of research analysts have weighed in on IONS shares. William Blair started coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, November 14th. They set a “market perform” rating on the stock. BidaskClub raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Morgan Stanley cut shares of Ionis Pharmaceuticals from an “equal” rating to a “weight” rating and reduced their price target for the company from $63.00 to $48.00 in a research report on Thursday, November 7th. TheStreet cut shares of Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, August 8th. Finally, Bank of America started coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, November 13th. They set a “buy” rating and a $70.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $75.55.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Featured Article: Conference Calls
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.